Skip to Content
Merck
CN

B5437

Bendamustine hydrochloride hydrate

≥98% (HPLC)

Synonym(s):

1H-Benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl monohydrochloride, Treanda

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C16H21Cl2N3O2·HCl · xH2O
CAS Number:
1374784-02-7
Molecular Weight:
394.72 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
329773260
UNSPSC Code:
12352200
MDL number:
MFCD16879055

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Bendamustine hydrochloride hydrate, ≥98% (HPLC)

InChI key

TWBJYCLUHINEDN-UHFFFAOYSA-N

SMILES string

O.Cl.Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl

InChI

1S/C16H21Cl2N3O2.ClH.H2O/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H;1H2

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

off-white

solubility

H2O: >30 mg/mL

originator

Teva

storage temp.

room temp

Quality Level

100

Application

Bendamustine hydrochloride hydrate has been used as:
  • a chemotherapy agent for chronic lymphocytic leukemia (CLL) samples to monitor spliced and unspliced gene expression
  • an inhibitor to E3 ubiquitin-protein ligase RNF3 (HOIP) in matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF) assay
  • a cytotoxic chemotherapeutic drug in high-throughput screening to test interaction with BAY87-2243

Biochem/physiol Actions

Bendamustine hydrochloride is a DNA-alkylator with a distinct pattern of activity. Bendamustine activates DNA-damage stress response and apoptosis; inhibits mitotic checkpoints; and induces mitotic catastrophe.
Bendamustine is a therapeutic agent employed in treating lymphomas and chronic lymphocytic leukemia. It may be useful in central nervous system (CNS) malignancies treatment regimen due to its penetration capacity into brain tissue. Bendamustine is a promising candidate for non-Hodgkin lymphoma and Hodgkin lymphoma therapies.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Teva. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Bendamustine comprises 2-chloroethylamine alkylating group, a butyric acid side chain and a benzimidazole ring in its structure and is a nitrogen mustard. It is catabolized in the liver by the enzyme cytochrome P450 1A2 into γ hydroxyl-bendamustine and N-desmethyl-bendamustine.

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Carc. 2 - Muta. 2 - Repr. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000160957
0000119568
0000119569
0000090887

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Therasa Kim et al.
BMC cancer, 18(1), 729-729 (2018-07-11)
A relatively high proportion of patients diagnosed with primary CNS lymphoma will experience recurrent disease, yet therapy options are limited in salvage therapy. This is the first study to evaluate a bendamustine-based combination regimen for the treatment of relapsed/refractory PCNSL
Sheridan M Hoy
Drugs, 72(14), 1929-1950 (2012-09-07)
Bendamustine (Levact®) is an alkylating agent consisting of three structural elements: a 2-chloroethylamine alkylating group; a butyric acid side chain; and a benzimidazole ring. Although its precise mechanism of action is as yet unknown, it appears to exert its antineoplastic
Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel-an update
Cheson BD, et al.
Leukemia Lymphoma, 57(4), 766-782 (2016)
Manoj K Kashyap et al.
Haematologica, 100(7), 945-954 (2015-04-12)
RNA splicing plays a fundamental role in human biology. Its relevance in cancer is rapidly emerging as demonstrated by spliceosome mutations that determine the prognosis of patients with hematologic malignancies. We report studies using FD-895 and pladienolide-B in primary leukemia
Elinor A Chapman et al.
Oncotarget, 8(61), 102948-102964 (2017-12-22)
The functional significance of AKT in chronic lymphocytic leukemia (CLL) remains unclear. Given the importance of non-malignant T cells in regulating clonal expansion in CLL, we investigated the role of AKT in T cell-mediated cytoprotection and proliferation using an established
View All Related Papers

Articles

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Bioactive Molecules for Apoptosis

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service